Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, Guangdong, People's Republic of China.
College of Medicine, Lishui University, Lishui, Zhejiang, People's Republic of China.
Respir Res. 2021 Oct 25;22(1):274. doi: 10.1186/s12931-021-01872-z.
Dysbiosis of the gut microbiome is involved in the pathogenesis of various diseases, but the contribution of gut microbes to the progression of chronic obstructive pulmonary disease (COPD) is still poorly understood.
We carried out 16S rRNA gene sequencing and short-chain fatty acid analyses in stool samples from a cohort of 73 healthy controls, 67 patients with COPD of GOLD stages I and II severity, and 32 patients with COPD of GOLD stages III and IV severity. Fecal microbiota from the three groups were then inoculated into recipient mice for a total of 14 times in 28 days to induce pulmonary changes. Furthermore, fecal microbiota from the three groups were inoculated into mice exposed to smoke from biomass fuel to induce COPD-like changes.
We observed that the gut microbiome of COPD patients varied from that of healthy controls and was characterized by a distinct overall microbial diversity and composition, a Prevotella-dominated gut enterotype and lower levels of short-chain fatty acids. After 28 days of fecal transplantation from COPD patients, recipient mice exhibited elevated lung inflammation. Moreover, when mice were under both fecal transplantation and biomass fuel smoke exposure for a total of 20 weeks, accelerated declines in lung function, severe emphysematous changes, airway remodeling and mucus hypersecretion were observed.
These data demonstrate that altered gut microbiota in COPD patients is associated with disease progression in mice model.
肠道微生物组的失调与各种疾病的发病机制有关,但肠道微生物对慢性阻塞性肺疾病(COPD)进展的贡献仍知之甚少。
我们对 73 名健康对照者、67 名 GOLD 分期 I 和 II 严重程度的 COPD 患者和 32 名 GOLD 分期 III 和 IV 严重程度的 COPD 患者的粪便样本进行了 16S rRNA 基因测序和短链脂肪酸分析。然后将来自这三组的粪便微生物群接种到接受者小鼠中,在 28 天内共进行了 14 次,以诱导肺部变化。此外,还将来自这三组的粪便微生物群接种到暴露于生物量燃料烟雾的小鼠中,以诱导类似 COPD 的变化。
我们观察到 COPD 患者的肠道微生物群与健康对照者不同,其特征是整体微生物多样性和组成明显不同,普雷沃氏菌主导的肠道肠型和短链脂肪酸水平较低。在接受者小鼠接受来自 COPD 患者的粪便移植 28 天后,其肺部炎症水平升高。此外,当小鼠同时接受粪便移植和生物质燃料烟雾暴露共 20 周时,观察到肺功能加速下降、严重肺气肿变化、气道重塑和粘液分泌过多。
这些数据表明,COPD 患者肠道微生物群的改变与小鼠模型中的疾病进展有关。